Drug Discovery & DDS Weekly Report May 31, 2026

Drug Discovery & DDS Weekly Report July 19, 2026

Antibody-Drug Conjugates (ADCs) Evolve to Standard of Care in Solid Tumor Treatment: 12 Approved, 300 in Development, Focusing on Patient Wellness and Dual-Payload Strategies

Targeted Protein Degradation (TPD) Enters Decisive Clinical Phase, Evolving Beyond PROTACs to Multifunctional Therapeutics

AI Transforms Drug Discovery: Generative AI Accelerates Molecule Design to Clinical Prediction, Reducing R&D Costs and Risks

SGN-CEACAM5C (PF-08046050) Antibody-Drug Conjugate Evaluated in Phase 1 Clinical Trial for Advanced Solid Tumors Including Colorectal Cancer

Phase 2 OPTIMAL-e Study Begins Dosing in Metastatic Hormone-Sensitive Prostate Cancer to Assess Adaptive Lutetium-177 PSMA RLT

GZL626, a Novel Molecular Glue Degrader for Androgen Receptor (AR/AR-V7), Overcomes Resistance in Advanced Prostate Cancer

ChemRxiv Unveils AI Workflow for Structure-Aware Small-Molecule Drug Design: Integrating Agentic, Explainable, and Generative AI for Design to Prioritization